| Guideline update for MASCC and ESMO in the prevention of chemotherapy-and radiotherapy-induced nausea and vomiting: results of the Perugia consensus conference F Roila, J Herrstedt, M Aapro, RJ Gralla, LH Einhorn, E Ballatori, E Bria, ... Annals of Oncology 21, v232-v243, 2010 | 870 | 2010 |
| Hyperprogressive disease in patients with advanced non–small cell lung cancer treated with PD-1/PD-L1 inhibitors or with single-agent chemotherapy R Ferrara, L Mezquita, M Texier, J Lahmar, C Audigier-Valette, ... JAMA oncology 4 (11), 1543-1552, 2018 | 683 | 2018 |
| COVID-19 in patients with thoracic malignancies (TERAVOLT): first results of an international, registry-based, cohort study MC Garassino, JG Whisenant, LC Huang, A Trama, V Torri, F Agustoni, ... The Lancet Oncology 21 (7), 914-922, 2020 | 646 | 2020 |
| Differential activity of nivolumab, pembrolizumab and MPDL3280A according to the tumor expression of programmed death-ligand-1 (PD-L1): sensitivity analysis of trials in … L Carbognin, S Pilotto, M Milella, V Vaccaro, M Brunelli, A Caliò, ... PloS one 10 (6), e0130142, 2015 | 521 | 2015 |
| Elacestrant (oral selective estrogen receptor degrader) versus standard endocrine therapy for estrogen receptor–positive, human epidermal growth factor receptor 2–negative … FC Bidard, VG Kaklamani, P Neven, G Streich, AJ Montero, F Forget, ... Journal of Clinical Oncology 40 (28), 3246, 2022 | 259 | 2022 |
| Benefit of taxanes as adjuvant chemotherapy for early breast cancer: pooled analysis of 15,500 patients E Bria, C Nistico, F Cuppone, P Carlini, M Ciccarese, M Milella, G Natoli, ... Cancer 106 (11), 2337-2344, 2006 | 210 | 2006 |
| Lung neuroendocrine tumours: deep sequencing of the four World Health Organization histotypes reveals chromatin‐remodelling genes as major players and a prognostic role for … M Simbolo, A Mafficini, KO Sikora, M Fassan, S Barbi, V Corbo, ... The Journal of pathology 241 (4), 488-500, 2017 | 195 | 2017 |
| Cardiotoxicity and incidence of brain metastases after adjuvant trastuzumab for early breast cancer: the dark side of the moon? A meta-analysis of the randomized trials E Bria, F Cuppone, M Fornier, C Nisticò, P Carlini, M Milella, I Sperduti, ... Breast cancer research and treatment 109, 231-239, 2008 | 195 | 2008 |
| PIK3CA mutations are associated with reduced pathological complete response rates in primary HER2-positive breast cancer: pooled analysis of 967 patients from five prospective … S Loibl, I Majewski, V Guarneri, V Nekljudova, E Holmes, E Bria, ... Annals of Oncology 27 (8), 1519-1525, 2016 | 188 | 2016 |
| Patients’ perception of chemotherapy side effects: Expectations, doctor–patient communication and impact on quality of life–An Italian survey D Lorusso, E Bria, A Costantini, M Di Maio, G Rosti, A Mancuso European journal of cancer care 26 (2), e12618, 2017 | 181 | 2017 |
| Randomized multicenter Phase II trial of two different schedules of irinotecan combined with capecitabine as first‐line treatment in metastatic colorectal carcinoma E Bajetta, M Di Bartolomeo, L Mariani, A Cassata, S Artale, S Frustaci, ... Cancer 100 (2), 279-287, 2004 | 162 | 2004 |
| Crizotinib in MET-Deregulated or ROS1-Rearranged Pretreated Non–Small Cell Lung Cancer (METROS): A Phase II, Prospective, Multicenter, Two-Arms Trial L Landi, R Chiari, M Tiseo, F D'Incà, C Dazzi, A Chella, A Delmonte, ... Clinical cancer research 25 (24), 7312-7319, 2019 | 153 | 2019 |
| Do adjuvant aromatase inhibitors increase the cardiovascular risk in postmenopausal women with early breast cancer: Meta‐analysis of randomized trials F Cuppone, E Bria, S Verma, KI Pritchard, S Gandhi, P Carlini, M Milella, ... Cancer: Interdisciplinary International Journal of the American Cancer …, 2008 | 146 | 2008 |
| The cardiovascular toxicity of abiraterone and enzalutamide in prostate cancer R Iacovelli, C Ciccarese, E Bria, M Romano, E Fantinel, D Bimbatti, ... Clinical genitourinary cancer 16 (3), e645-e653, 2018 | 145 | 2018 |
| Molecular typing of lung adenocarcinoma on cytological samples using a multigene next generation sequencing panel A Scarpa, K Sikora, M Fassan, AM Rachiglio, R Cappellesso, D Antonello, ... PloS one 8 (11), e80478, 2013 | 144 | 2013 |
| Brain metastases from solid tumors: disease outcome according to type of treatment and therapeutic resources of the treating center A Fabi, A Felici, G Metro, A Mirri, E Bria, S Telera, L Moscetti, M Russillo, ... Journal of Experimental & Clinical Cancer Research 30, 1-7, 2011 | 134 | 2011 |
| Role of mTOR signaling in tumor microenvironment: an overview F Conciatori, C Bazzichetto, I Falcone, S Pilotto, E Bria, F Cognetti, ... International Journal of Molecular Sciences 19 (8), 2453, 2018 | 132 | 2018 |
| mTOR cross-talk in cancer and potential for combination therapy F Conciatori, L Ciuffreda, C Bazzichetto, I Falcone, S Pilotto, E Bria, ... Cancers 10 (1), 23, 2018 | 131 | 2018 |
| Physical activity and exercise in lung cancer care: will promises be fulfilled? A Avancini, G Sartori, A Gkountakos, M Casali, I Trestini, D Tregnago, ... The oncologist 25 (3), e555-e569, 2020 | 130 | 2020 |
| Gemcitabine‐based combinations for inoperable pancreatic cancer: Have we made real progress? A meta‐analysis of 20 phase 3 trials E Bria, M Milella, A Gelibter, F Cuppone, MS Pino, EM Ruggeri, P Carlini, ... Cancer: Interdisciplinary International Journal of the American Cancer …, 2007 | 130 | 2007 |
Diana GiannarelliFondazione Policlinico Universitario A. Gemelli IRCCS RomeVerified email at policlinicogemelli.it
